Landipirdine
Landipirdine is a serotonin 5-HT2A and 5-HT6 receptor antagonist which was under development for the treatment of dementia and cognition disorders but was never marketed. It is taken orally. The drug was developed by Roche, Accorda Therapeutics, and Biotie Therapies. It reached phase 2 clinical trials for dementia and phase 1 trials for cognition disorders prior to the discontinuation of its development in 2020. Landipirdine was first described in the scientific literature by at least 2010.